Skip to main content
LUCD logo

Lucid Diagnostics Inc. (LUCD) Stock Price & Analysis

Lucid Diagnostics Inc. (LUCD) — MoonshotScore 16/100 (Weak band), calculated Nov 22, 2026. Price $0.3727 (-3.52%), as of the Nov 20, 2026 trading session; market cap $72.6M.

Educational signal · not a buy or sell recommendation · How to read this

$0.3727 −$0.0136 (-3.52%) Market Cap $72.6M

Lucid Diagnostics Inc. · LUCD · NASDAQ

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company focused on patients with gastroesophageal reflux disease. The company's lead products, EsoGuard and EsoCheck, are designed for the early detection of esophageal precancer and cancer.

Price as of Nov 20, 2026

Key Statistics

16 of 100

MoonshotScore v2 · Lucid Diagnostics (LUCD)

Weak
Business Quality Poor (9)
Financial Safety Fragile (3)
Valuation Bubble (6)
Growth Durability Fading (28)
Momentum Slipping (25)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a fragile balance sheet and weak growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Slipping.

  • quarterly revenue $1M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z -19.43 · Piotroski F 2

Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LUCD (58 recorded, newest six shown)
RecordedScoreBand
16Weak
15Weak
15Weak
16Weak
16Weak
16Weak

The score was 16 in the stored Nov 21, 2026 snapshot and remains 16 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Growth Durability -1 and Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.3727
Change on the day-3.52%
52-week range$0.303 – $1.63
Market capitalisation$72.6M
Shares traded on the day2.26M

Price & events

Other perspectives

Council score for Lucid Diagnostics (LUCD): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Negative
Valuation Negative
Growth Durability Weak
Momentum Weak

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 22, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Negative
ROE Negative
Gross Margin Negative

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Lucid Diagnostics (LUCD), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Lucid Diagnostics Inc. (LUCD) is listed on NASDAQ. It employs 82 people and is led by Lishan Aklog. In Q3 FY2025 it reported revenue of $1M and net income of -$10M. The market values it at $72.6M.

2 · Latest results

What do the latest results show for Lucid Diagnostics (LUCD)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $1M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$1M-$10M-$0.10 (diluted)
Q4 FY2025$2M-$16M-$0.10 (diluted)
Q1 FY2026$1M-$14M-$0.17 (diluted)
Q2 FY2026$1M-$12M-$0.08 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Lucid Diagnostics (LUCD)?

Short answer

What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -19.43 · Piotroski F 2. Trailing ratios: ROA -79.0% · current ratio 1.20.

Data-derived red flags

  • Listing risk — at $0.3727 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -19.43 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Lucid Diagnostics (LUCD)?

Short answer · as of

The stored analyst-target capture is expired, so a current target watchpoint is unavailable.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • The newest quarter held here (Q3 FY2025) was filed Nov 12, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Lucid Diagnostics compare with its peers?

Short answer

Lucid Diagnostics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Electromed, Inc. (ELMD) Same industry, near in market value$22.98 Nov 20, 2026$188M88 5-pillar Nov 22, 2026
Viemed Healthcare, Inc. (VMD) Same industry, near in market value$8.52 Nov 20, 2026$323M88 5-pillar Nov 22, 2026
BrainsWay Ltd. (BWAY) Same industry, near in market value$8.48 Nov 20, 2026$333M86 5-pillar Nov 22, 2026
Anika Therapeutics, Inc. (ANIK) Same industry, near in market value$13.23 Nov 20, 2026$177M72 5-pillar Nov 22, 2026
Solana Company (HSDT) Same industry, near in market value$1.49 Nov 20, 2026$93.7M43 5-pillar Nov 22, 2026
LENSAR, Inc. (LNSR) Same industry, near in market value$4.46 Nov 20, 2026$54.8M43 5-pillar Nov 22, 2026
Owlet, Inc. (OWLT) Same industry, near in market value$2.93 Nov 20, 2026$87.6M41 5-pillar Nov 22, 2026
Hyperion DeFi, Inc. (HYPD) Same industry, near in market value$2.08 Nov 20, 2026$31.5M38 5-pillar Nov 22, 2026
Inogen, Inc. (INGN) Same industry, near in market value$5.30 Nov 20, 2026$138M37 5-pillar Nov 22, 2026
Orthofix Medical Inc. (OFIX) Same industry, near in market value$6.07 Nov 20, 2026$247M36 5-pillar Nov 22, 2026
908 Devices Inc. (MASS) Same industry, near in market value$8.67 Nov 20, 2026$361M35 5-pillar Nov 22, 2026
Sight Sciences, Inc. (SGHT) Same industry, near in market value$10.18 Nov 20, 2026$566M34 5-pillar Nov 22, 2026
Lucid Diagnostics (LUCD) — this page$0.3727$72.6M16

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
$2.00 – $2.00
Last captured analyst target (expired, captured Nov 18, 2026)
$2.00
Last captured median analyst target (expired, captured Nov 18, 2026)
$2.00

Historical target record · Captured · Capture expired; not a current watchpoint.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LUCD in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LUCD in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Lucid Diagnostics (LUCD)?

Read these with our analysis →

Common Questions About LUCD

These answers are editorial: 1 of these 9 answers is drawn from the LUCD research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for LUCD?

LUCD carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company focused on patients with gastroesophageal reflux disease.

Is LUCD a good stock to buy?

Stock Expert AI does not rate LUCD buy, sell or hold. Lucid Diagnostics Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the LUCD stock price today?

The last price recorded for Lucid Diagnostics Inc. (LUCD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the LUCD price target?

The last analyst consensus price target we captured for Lucid Diagnostics Inc. (LUCD), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.

What are the key growth opportunities for LUCD in healthcare?

Lucid Diagnostics Inc. has several key growth opportunities within the healthcare sector. A primary driver is the expansion of adoption for its EsoGuard and EsoCheck products among the large population of GERD patients at risk for esophageal precancer.

What are the key factors to evaluate for LUCD?

Lucid Diagnostics Inc. (LUCD) holds a MoonshotScore in the low range. Not financial advice.

How frequently does LUCD data refresh on this page?

LUCD's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven LUCD's recent stock price performance?

Lucid Diagnostics Inc. (LUCD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Commercial-stage company with active product offerings (EsoGuard and EsoCheck). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider LUCD overvalued or undervalued right now?

Lucid Diagnostics Inc. (LUCD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 12 from Financial Modeling Prep (FMP), 5 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.